Compare Conagra Brands Inc (CAG) vs Medpace Holdings Inc (MEDP) Price & Performance

Conagra Brands (CAG) trades at $15.06, up 1.89% with mixed technical signals showing neutral overall momentum. The company faces fundamental challenges with negative net income margin (-16.99%) and ROE (-25.06%) despite recent earnings beats. Recent developments include a 50% dividend cut to $0.18, new executive appointments, and strategic shifts under CEO John Brase to address margin pressure and declining sales.

While CAG's low valuation (P/E 10.06, P/S 0.63) offers potential upside, persistent revenue declines and margin compression present significant headwinds. Analyst consensus remains cautious with 62.5% hold ratings, though the company's debt reduction efforts and operational simplification could support a turnaround if execution improves.

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.